Trial Profile

A Long-Term, Real-World Evidence Study to Evaluate the Real-World Effectiveness of Emgality (galcanezumab-gnlm) Compared to Other Preventive Treatments for Migraine in People Receiving Routine Medical Care who are Switching or Beginning a New Prescription Treatment for Migraine Prevention

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jun 2022 Interim results (n=1954) of preliminary analysis assessing burden of migraine and comparing galcanezumab group with other treatment presented at the 64th Annual Scientific Meeting of the American Headache Society
12 Jun 2022 Interim results presented at the 64th Annual Scientific Meeting of the American Headache Society
24 Dec 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com